CDC Just Forecast $82.5 Million for Harm Reduction Services. Only Two Organizations Will Win It.

Community-based organizations serving people who use drugs — rural clinics, tribal health programs, and faith-based outreach ministries — now have ten months of warning that CDC intends to move $82.5 million through CDC-RFA-PS-27-0239, a forecast posted to Grants.gov on July 24.

That sentence contains two facts worth separating. The first is the money, and it is real. The second is the word forecast, and it changes almost everything about how a small organization should respond.

The Grants.gov Listing Is a Forecast, Not an Open Competition

Pull up opportunity 363310 and the fields tell a specific story. CDC's National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) posted the forecast on July 24, 2026. Estimated total program funding: $82,500,000. Expected number of awards: two. Award ceiling and floor: unspecified. Funding instrument: cooperative agreement. Cost sharing: not required. Assistance listing: 93.488.

The dates matter more than the dollars right now. CDC estimates it will post the actual synopsis — the real notice of funding opportunity, with the real application package — on March 24, 2027. Estimated application due date: May 24, 2027, at 11:59 p.m. ET. Estimated award date: August 30, 2027. Estimated project start: September 30, 2027. The forecast archives on June 23, 2027.

So nothing is open. There is no application package to download, no SF-424 to start, no page limit to plan against. What exists is ten months of notice, which in federal grant terms is an unusual gift and a very specific kind of trap. Organizations that treat a forecast like an open NOFO burn staff time drafting narrative against requirements that do not exist yet. Organizations that ignore forecasts entirely show up in March with sixty days to assemble a competitive application for a national cooperative agreement. Neither is the move.

Read the Assistance Listing Title Before You Read the Abstract

Here is the detail that should reset expectations for most community-based organizations, and it sits in a field almost nobody reads. Assistance listing 93.488 carries the program title: National Harm Reduction Technical Assistance and Syringe Services Program (SSP) Monitoring and Evaluation Funding Opportunity.

Technical assistance. Monitoring and evaluation. National.

This is not a grant that pays a rural syringe services program to buy naloxone, staff a mobile unit, or run hepatitis C testing in a county with no health department clinic. It is the award that builds and operates the national data and support infrastructure sitting above those programs. The abstract confirms it. Component 1 funds a biennial survey of high-impact settings serving people who use drugs — documenting capacity, needs, access, and service gaps — plus a biennial biobehavioral survey of people who use drugs themselves, to generate timely local data on infectious disease consequences and on testing, treatment, and prevention uptake. Component 2 supports the availability and use of infectious disease testing, treatment, and prevention services in those settings. Applicants may apply for Component 1, Component 2, or both.

Two awards. $82.5 million. National scope. That arithmetic describes intermediaries, not direct service grantees.

What the Predecessor Cycle Actually Paid, and to Whom

The pattern is documented, because this cooperative agreement has a direct ancestor. In September 2022, CDC made two awards totaling roughly $7.7 million in the first project year under CDC-RFA-PS22-2208, "Strengthening Syringe Services Programs," a five-year program. The split by component was lopsided:

• Component 1 — $749,934 to RTI International, to support a national SSP network and run the annual survey of SSP capacity and service delivery.
• Component 2 — $6,954,478 to the National Alliance of State and Territorial AIDS Directors (NASTAD), to expand the reach of SSPs preventing the infectious consequences of injection drug use and overdose.

Two national organizations. One data contractor, one membership association with the infrastructure to move money and support outward to local programs. If PS-27-0239 follows the same shape — and the component structure, the award count, and the assistance listing all suggest it will — the realistic path for a small community-based organization is not prime applicant. It is subrecipient, network member, or survey respondent.

That is a demotion in ambition and an upgrade in odds. A tribal health program in Montana is not going to out-compete RTI for a national biobehavioral survey. That same program can absolutely be the local partner a Component 2 applicant names in its application, budgets for, and subawards to — and being named in a winning application in May 2027 is how money reaches your organization in September 2027.

One caveat on the headline number: $82.5 million is the estimated total for the program, while the $7.7 million figure above was a first-year amount across both PS22-2208 awards. The comparison is not apples to apples. But even annualized across a five-year period, PS-27-0239 reads as a meaningful expansion of the same function rather than a flat renewal.

It is also worth noting a genuine change between cycles. PS22-2208 ran an annual survey of syringe services programs. PS-27-0239 describes a biennial survey of high-impact settings, plus a new biennial biobehavioral survey of people who use drugs. Less frequent institutional counting, new individual-level measurement. If your program's service data has been feeding the national survey, expect both the cadence and the instrument to change.

The Coverage Gap the Survey Is Being Built to Measure

The reason any of this reaches rural and tribal organizations is that the geography of harm reduction is severely lopsided, and CDC knows it. Most urban counties in the United States have at least one operational syringe services program. Among rural counties, the figure is 6.7 percent.

Demand is not the constraint. A 2025 study in a northern Midwest American Indian community found 56 percent of people who had recently used drugs said they would use a syringe services program if one were available. Among Indigenous people who inject drugs in rural Montana, 98 percent expressed interest in using a harm reduction program. The services are wanted in precisely the places they do not exist.

Eligibility on the forecast is broad in a way that reflects this. Listed applicant types include federally recognized tribal governments, other Native American tribal organizations, county and city governments, nonprofits both with and without 501(c)(3) status, public and private institutions of higher education, independent school districts, and public housing authorities — with an "unrestricted" flag on top. Nonprofits without 501(c)(3) status being explicitly named is not boilerplate; it is the field acknowledging that a meaningful share of the organizations doing this work do not have clean federal paperwork. That same eligibility breadth is what makes community nonprofits viable on federal direct-service money generally — the pattern behind the VA's $112 million SSG Fox suicide prevention program, where community organizations, not health systems, were the intended grantees.

What to Do Between Now and March 24

Ten months of lead time is only valuable if you spend it on work that survives contact with the real NOFO. Four things that will:

Get counted. If your organization serves people who use drugs and has never appeared in the national SSP survey, fix that first. Component 1's entire premise is a census of high-impact settings. Programs invisible in the data are invisible in the needs analysis that justifies where Component 2 dollars land.

Get registered. SAM.gov registration and renewal is the single most common reason organizations miss federal deadlines they otherwise would have met. Renewal can take weeks. There is no reason to be discovering an expired registration in May 2027.

Identify your prime. Watch which national organizations and state health departments position for Component 2, and open the conversation about being a named subrecipient before the synopsis posts. Partnership letters get assembled in the last two weeks of an application cycle; relationships do not.

Build the local numbers now. Testing volumes, hepatitis C treatment initiations, HIV linkage-to-care counts, service-gap documentation for your county or reservation. Whoever writes the winning Component 2 application needs exactly this to justify a subaward to you, and they need it in April 2027, not August.

One more piece of realism: forecasts slip, get restructured, or quietly disappear. The dates on opportunity 363310 are estimates, and a March 2027 synopsis posting sits inside a federal budget cycle that has been anything but predictable for public health funding. Plan so the work is useful even if this specific NOFO changes shape — the data, the registration, and the partnership all serve other applications.

The named CDC contact on the forecast is Monica Adams (404-718-5092, ydy7@cdc.gov). Program contacts on forecasts generally will not discuss competitive strategy, but they can confirm whether a synopsis is still on schedule — a five-minute call in February 2027 worth making.

Next step: Search active harm reduction and syringe services funding on Granted to find what is open right now, while PS-27-0239 sits ten months out.